nach oben

Pediatric Nephrology

Erschienen in:

01.10.2004 | Review

A 20-year history of childhood HIV-associated nephropathy

verfasst von: Patricio E. Ray, Lian Xu, Tamara Rakusan, Xue-Hui Liu

Erschienen in: Pediatric Nephrology | Ausgabe 10/2004

Einloggen, um Zugang zu erhalten

Abstract

In 1984, physicians in New York and Miami reported HIV-infected adult patients with heavy proteinuria and rapid progression to end-stage renal disease. These patients showed large edematous kidneys with a combination of focal segmental glomerulosclerosis (FSGS) and tubulointerstitial lesions. This renal syndrome, named HIV-associated nephropathy (HIVAN), was found predominantly in African Americans. Subsequent studies confirmed the presence of HIVAN in children, who frequently develop nephrotic syndrome in association with FSGS and/or mesangial hyperplasia with microcystic tubular dilatation. Since then, substantial progress has been made in our understanding of the etiology and pathogenesis of HIVAN. This article reviews 20 years of research into the pathogenesis of HIVAN and discusses how these concepts could be applied to the treatment of children with HIVAN. HIV-1 infection plays a direct role in the pathogenesis of childhood HIVAN, at least partially by affecting the growth and differentiation of glomerular and tubular epithelial cells and enhancing the renal recruitment of infiltrating mononuclear cells and cytokines. An up-regulation of renal heparan sulfate proteoglycans seems to play a relevant role in this process, by increasing the recruitment of heparin-binding growth factors (i.e., FGF-2), chemokines, HIV-infected cells, and viral proteins (i.e., gp120, Tat). These changes enhance the infectivity of HIV-1 in the kidney and induce injury and proliferation of intrinsic renal cells. Highly active anti-retroviral therapy (HAART) appears to be the most promising treatment to prevent the progression of childhood HIVAN. Hopefully, in the near future, better education, prevention, and treatment programs will lead to the eradication of this fatal childhood disease.

Pneumocystis pneumonia—Los Angeles (1981) Morb Mortal Wkly. Rep 30:250–252

Fauci AS (1999) The AIDS epidemic—considerations for the 21st century. N Engl J Med 341:1046–1050CrossRefPubMed

Barre-Sinoussi F, Chermann JC, Rey F, Nugeyre MT, Chamaret S, Gruest J, Dauguet C, Axler-Blin C, Vezinet-Brun F, Rouzioux C, Rozembaum W, Montagnier L (1983) Isolation of a T lymphtropic retrovirus from at patient at risk for acquired immune deficiency (AIDS). Science 220:868–871PubMed

Gallo RC (2002) Human retrovirus after 20 years: a perspective from the past and prospects for their future control. Immunol Rev 185:236–265CrossRefPubMed

Mitsuya H, Weinhold KJ, Furman PA, St Clair MH, Lehrman SN, Gallo RC, Bolognesi D, Barry DW, Broders S (1985) 3’-Azido-3’-deoxytimidine (BW A509U): an antiviral agent that inhibits the infectivity and cytopathic effect of human T-lymphotropic virus type III/lymphadenopathy-associated virus in vitro. Proc Natl Acad Sci USA 82:7096–7100PubMed

Oleske J, Minnefor A, Cooper R, Thomas K, Cruz A dela, Ahdieh H, Guerrero I, Joshi VV, Deposito F. (1983) Immune deficiency syndrome in children. JAMA 249:2345–2349CrossRefPubMed

Rubinstein A, Sicklick M, Gupta A, Bernstein L, Klein N, Rubisntein E, Spigland I, Fruchter L, Litman N, Lee H, Hollander M (1983) Acquired immunodeficiency with reversed T4/T8 ratios in infants born to promiscuous and drug-addicted mothers. JAMA 249:2350–2356CrossRefPubMed

Cowan MJ, Hellmann D, Chudwin D, Wara DW, Chang RS, Ammann AJ (1984) Maternal transmission of acquired immune deficiency syndrome. Pediatrics 73:382–386PubMed

Lindegren ML, Steinberg S, Byers RH (2000) Epidemiology of HIV/AIDS in children. Pediatr Clin North Am 47:1–38PubMed

10.

Centers for Disease Control and Prevention (2001) HIV/AIDS Surv Rep 13:1–44

11.

The Global HIV and AIDS Epidemic (2001) Morb Mortal Wkly 50:439

12.

Connor E, Gupta S, Joshi V, DiCarlo F, Offenberger J, Minnefor A, Uy C, Oleske J, Ende N (1988) Acquired immunodeficiency syndrome-associated renal disease in children. J Pediatr 113:39–44PubMed

13.

Strauss J, Abitol C, Zilleruelo G, Scott G, Paredes A, Malaga S, Montane B, Mitchell C, Parks W, Pardo V (1989) Renal disease in children with acquired immunodeficiency syndrome. N Engl J Med 321:625–630PubMed

14.

Tarshish P (1991) Approach to the diagnosis and management of HIV-associated nephropathy. J Pediatr 119:S50–S56PubMed

15.

Joshi VV (1991) Pathology of childhood AIDS. Pediatr Clin North Am 84:11–13

16.

Ingulli E, Tejani A, Fikrig S, Nicastri A, Chen CK, Pomrantz A (1991) Nephrotic syndrome associated with acquired immunodeficiency syndrome in children. J Pediatr 119:710–716PubMed

17.

Turner ME, Kher K, Rakussan T, D’Angelo LM, Kapur S, Selby D, Ray PE (1997) Atypical hemolytic-uremic syndrome in HIV-1 infected children. Pediatr Nephrol 11:161–163CrossRefPubMed

18.

Ray PE, Rakusan T, Loechelt BJ, Selby DM, Liu X-H, Chandra RS (1998) Human immunodeficiency virus (HIV)-associated nephropathy in children from the Washington, D.C. area: 12 years’ experience. Semin Nephrol 18:396–405PubMed

19.

Rao TKS, Friedman EA, Nicastri AD (1987) The types of renal disease in the acquired immunodeficiency syndrome. N Engl J Med 316:1062–1068PubMed

20.

Stine GJ (2002) AIDS update. An annual overview of acquired immune deficiency syndrome. Biological characteristics of the AIDS virus. Prentice Hall, Upper Saddle River, New Jersey, pp 52–71

21.

Stevenson (2003) HIV pathogenesis. Nat Med 9:853–860CrossRefPubMed

22.

Shirai A, Klinman DM (1993) Immunization with recombinant gp160 prolongs the survival of HIV-transgenic mice. AIDS Res Hum Retroviruses 9:979–983PubMed

23.

Kopp JB, Barisoni L (2002) Modulation of podocytes phenotype in collapsing glomerulopathy. Microsc Res Tech 57:254–262CrossRefPubMed

24.

Conaldi PG, Botelli A, Baj A, Serra C, Fiore L, Federico G, Bussolati B, Camussi G (2002) Human immunodeficiency virus-1 Tat induces hyperproliferation and dysregulation of renal glomerular epithelial cells. Am J Pathol 161:53–61PubMed

25.

Klotman PE, Ross MJ (2002). Recent progress in HIV-associated nephropathy. J Am Soc Nephrol 13:2997–3004PubMed

26.

Dickie P, Felser J, Eckhaus ME, Bryant J, Silver J, Marinos N, Notkins AL (1991) HIV-associated nephropathy in transgenic mice expressing HIV-I genes. Virology 185:109–119CrossRefPubMed

27.

Kopp JB, Klotman ME, Adler SH, Bruggeman L, Dickie P, Bryant J, Notkins A, Klotman PE (1992) Progressive glomerulosclerosis and enhanced renal accumulation of basement membrane components in mice transgenic for human immunodeficiency virus type 1 genes. Proc Natl Acad Sci USA 89:1577–1581PubMed

28.

Reid W, Sadowska M, Denaro F, Rao S, Foulke Jr J, Hayes N, Jones O, Doodnauth D, Davis H, Sill A, O’Driscoll P, Huso D, Fouts T, Lewis G, Hill M, Kamin-Lewis R, Wei C, Ray PE, Gallo RC, Reitz M, Bryant J (2001) An HIV-1 transgenic rat that develops HIV-related pathology and immunology dysfunction. Proc Natl Acad Sci USA 98:9271–9276CrossRefPubMed

29.

Ray PE, Liu X-L, Robinson RL, Reid W, Xu L, Owens JW, Jones OD, Denaro F, Davis HG, BryantJL (2003) A novel HIV-1 transgenic rat model of childhood HIV-1 associated nephropathy. Kidney Int 63:2242–2253CrossRefPubMed

30.

Rao TK, Filippone EJ, Nicastri AD, Landesman SH, Frank S, Chen CK, Friedman EA (1984) Associated focal and segmental glomerulosclerosis in the acquired immunodeficiency syndrome. N Engl J Med 310:669–673PubMed

31.

Pardo V, Aldana M, Colton RM, Fischl MA, Jaffe D, Moskowitz L, Hensley T, Bourgoignie JJ (1984) Glomerular lesions in the acquired immunodeficiency syndrome. Ann Intern Med 101:429–434PubMed

32.

Gardenswartz MH, Lerner CW, Seligson GR, Zabetakis PM, Rotterdam H, Tapper ML, Michelis MF, Bruno MS (1984) Renal disease in patients with AIDS: a clinicopathological study. Clin Nephrol 21:197–204PubMed

33.

Cohen AH, Nast CC (1988) HIV-associated nephropathy: a unique combined glomerular, tubular and interstitial lesion. Mod Pathol1:87–97

34.

D’Agatii V, Appel GB (1997) HIV infection and the kidney. J Am Soc Nephrol 8:138–152PubMed

35.

Pardo V, Meneses R, Ossa L, Jaffe DJ, Strauss J, Roth D, Bourgoignie JJ (1987) AIDS-related glomerulopathy. Occurrence in specific risk groups. Kidney Int 31:1167–1173PubMed

36.

Kopp JB, Winkler C (2003) HIV-associated nephropathy in African Americans. Kidney Int 83:S43–S49

37.

Freedman BI, Soucie JM, Stone SM, Pegram S (1999) Familial clustering of end stage renal disease in blacks with HIV-associated nephropathy. Am J Kidney Dis 34:254–258PubMed

38.

Ray PE, Liu X-H, Xu L, Rakusan T (1999) Accumulation of bFGF in children with HIV-1 associated hemolytic uremic syndrome. Pediatr Nephrol 13:586–593CrossRefPubMed

39.

Ray PE, Liu XH, Henry D, Dye L, Xu L, Orenstein JM, Schuztbank TE (1998) Infection of human primary renal epithelial cells with HIV-1 from children with HIV-associated nephropathy. Kidney Int 53:1217–1229CrossRefPubMed

40.

Scheel PJ, Farzadegan H, Ford D, Malan M, Watson A (1995) Recovery of human immunodeficiency virus from peritoneal dialyis effluent. J Am Soc Nephrol 5:1926–1929PubMed

41.

Ray PE, Bruggeman L, Weeks B, Kopp J, Bryant J, Owens, Notkins A, Klotman PE (1994) Role of bFGF and its low affinity receptors in the pathogenesis of HIV-associated nephropathy in transgenic mice. Kidney Int 46:759–772PubMed

42.

Liu X-H, Achim A, Xu L, Wellstein A, Ray PE (2001) Up-regulation of a fibroblast growth factor binding protein in children with renal diseases. Kidney Int 59:1850–1858CrossRefPubMed

43.

Ray PE (1999) Looking into the past and future of HIV-nephropathy. Kidney Int 55:1123–1124CrossRefPubMed

44.

Bruggeman LA, Dikman S, Meng C, Quaggin SE, Coffman TM, Klotman PE (1997) Nephropathy in human immunodeficiency virus-1 transgenic mice is due to renal transgene expression. J Clin Invest 100:84–92PubMed

45.

Schwartz EJ, Cara A, Snoeck H, Ross MD, Sunamoto M, Reiser J, Mundel P, Klotman PE (2001) Human immunodeficiency virus-1 induces loss of contact inhibition in podocytes. J Am Soc Nephrol 12:1677–1684PubMed

46.

Barisoni L, Bruggeman LA, Mundel P, D’Agati V, Klotman PE (2000) HIV-1 induces renal epithelial dedifferentiation in a transgenic model of HIV-associated nephropathy. Kidney Int 58:173–181CrossRefPubMed

47.

Barisoni L, Kriz W, Mundel P, D’ Agati V (1999) The dysregulated podocyte phenotype: a novel concept in the pathogenesis of collapsing idiopathic focal segmental glomerolusclerosis and HIV-associated nephropathy. J Am Soc Nephrol 10:51–61CrossRefPubMed

48.

Barisoni L, Mokrzycki M, Sablay L, Nagata M, Yamase H, Mundel P (2000) Podocyte cell cycle regulation and proliferation in collapsing glomerulopathies. Kidney Int 58:137–143CrossRefPubMed

49.

Shankland SJ, Eitner F, Hudkins KL, GoodPaster T, D’Agati V, Alpers C (2000) Differential expression of cyclin-dependent kinase inhibitors in human glomerular disease: role in podocyte proliferation and maturation. Kidney Int 58:674–683CrossRefPubMed

50.

Nelson PJ, Gelman IH, Klotman PE (2001) Suppression of HIV-1 expression by inhibitors of cyclin-dependent kinases promotes differentiation of infected podocytes. J Am Soc Nephrol 12:2827–2831PubMed

51.

Kimmel PL, Barisoni L, Kopp JB (2003) Pathogenesis and treatment of HIV-associated renal disease: lessons from clinical and animal studies, molecular pathologic correlations and genetic investigations. Ann Intern Med 139:214–226PubMed

52.

Peterman AT, Pippin J, Hiromura K, Monkawa T, Durvasula R, Couser WG, Kopp J, Shankland SJ (2003) Mitotic cell cycle proteins increase in podocytes despite lack of proliferation. Kidney Int 63:113–122CrossRefPubMed

53.

Green DF, Resnick L, Bourgoignie JJ (1992) HIV infects glomerular endothelial and mesangial but not epithelial cells in vitro. Kidney Int 41:956–960PubMed

54.

Tokizawa S, Shimizu N, Hui-Yu L, Deyu F, Haraguchi Y, Oite T, Hoshino H (2000) Infection of mesangial cell with HIV and SIV: identification of GPR1 as a coreceptor. Kidney Int 58:607–617CrossRefPubMed

55.

Conaldi PG, Bottelli A, Wade-Evans A, Biancone L, Baj A, Cantaluppi V, Serra C, Dolei A, Toniolo A, Camussi G (2000) HIV-persistent infection and cytokine induction in mesangial cells: a potential mechanism for HIV-associated glomerulosclerosis. AIDS 14:2045–2047CrossRefPubMed

56.

diBelgiojoso GB, Genderini A, Vago L, Parravicini C, Bertoli S, Landriani N (1990) Absence of HIV antigens in renal tissue from patients with HIV-associated nephropathy. Nephrol Dial Transplant 5:489–492PubMed

57.

Alpers CE, McClure J, Bursten SL (1992) Human mesangial cells are resistant to productive infection by multiple strains of human immunodeficiency virus types 1 and 2. Am J Kidney Dis 19:126–130PubMed

58.

Eitner F, Cui Y, Hudkins KL, Stokes MB, Segerer S, Mack M, Lewis PL, Abraham AA, Schlondorff D, Gallo G, Kimmel PL, Alpers CE (2000) Chemokine receptor CCR5 and CXCR4 expression in HIV-associated kidney disease. J Am Soc Nephrol 11:856–867

59.

Tinkle BT, Ngo L, Luciw PA, Maciag T, Jay G (1977) HIV-associated vasculopathy in transgenic mice. J Virol 71:4809–4814

60.

Tinkle BT, Ueda H, Ngo L, Luciw PA, Shaw K, Rosen CA, Jay G (1997) Transgenic dissection of HIV genes involved in lymphoid depletion. J Clin Invest 100:32–39PubMed

61.

Striker LJ, Peten EP, Elliot SJ, Doi T, Striker G (1991) Biology of disease. Mesangial cell turnover: effect of heparin and peptide growth factors. Lab Invest 64:446–456PubMed

62.

Cohen AH, Sun NCJ, Shapshak P, Imagawa DT (1989) Demonstration of human immunodeficiency virus in renal epithelium in HIV-associated nephropathy. Mod Pathol 1:87–97

63.

Kimmel PL, Ferreira-Centeno A, Farkas-Szallazi T, Abraham AA, Garret CT (1993) Viral DNA in microdissected renal biopsy tissue from HIV infected patients with nephrotic syndrome. Kidney Int 43:373–378

64.

Conaldi PG, Biancone L, Botelli A, Wasde-Evans A, Racusen LC, Boccellino M, Orlandi V, Serra C, Camussi G, Toniolo A (1998) HIV-1 kills renal tubular epithelial cells in vitro by triggering an apoptotic pathway involving caspase activation and Fas upregulation. J Clin Invest 102:2041–2049PubMed

65.

Eitener F, Cui Y, Hudkins KL, Anderson DM, Schmidt A, Morton WR, Alpers CE (1998) Chemokine receptor (CCR5) expression in human kidneys and in the HIV infected macaque. Kidney Int 54:1945–1954CrossRefPubMed

66.

Bourinbaiar AS, Phillips DM (1991) Transmission of human immunodeficiency virus from monocytes to epithelial. J Acquir Immune Defic Syndr 4:56–63PubMed

67.

Bomsel M (1997) Transcytosis of infectious human immunodeficiency virus across a tight human epithelial cell line barrier. Nat Med 3:42–47PubMed

68.

Marechal V, Prevost MC, Petit C, Perret E, Heard JM, Schwartz O (2001) Human immunodeficiency virus type 1 entry into macrophages mediated macropinocytosis. J Virol 75:11166–11177CrossRefPubMed

69.

O’ Donnell MP, Chao CC, Gekker G, Modi KS, Kasiske BL, Keane WF (1998) Renal cell cytokine production stimulates HIV-1 expression in chronically HIV-infected monocytes. Kidney Int 53:593–597CrossRefPubMed

70.

Mack M, Kleinschmidt A, Bruhl H, Klier C, Nelson PJ, Cihak J, Plachy J, Stangassinger M, Erfle V, Schlondoerff D (2000) Transfer of the chemokine receptor CCR5 between cells by membrane-derived microparticles: a mechanism for cellular human immunodeficiency virus 1 infection. Nat Med 6:769–775CrossRefPubMed

71.

Meng G, Wei X, Wu X, Sellers MT, Decker JM, Moldoveanu Z, Orenstein JM, Graham MF, Kappes JC, Mestecky J, Shaw GM, Smith PD (2002) Primary intestinal epithelial cells selectively transfer R5 HIV-1 to CCR5⁺ cells. Nat Med 8:150–156CrossRefPubMed

72.

Bomsel M, David V (2002) Mucosal gatekeepers: selecting HIV viruses for early infection. Nat Med 8:114–116CrossRefPubMed

73.

Liu X-H, Lingwood CA, Ray PE (1999) Recruitment of renal tubular epithelial cells expressing verotoxin-1 (Stx-1) receptors in HIV-1 transgenic mice with renal disease. Kidney Int 55:554–561CrossRefPubMed

74.

Puri A, Hug P, Jernigan K, Bkarchi H, Kim Y, Hamilton J, Wiels J, Murrray GJ, Brady RO, Blumenthal R (1998). The neutral glycosphingolipid globotriasylceramide promotes fusion mediated by CD4-dependent CXCR4-utilizing HIV-1 envelope glycoprotein. Proc Natl Acad Sci USA 95:14435–14440CrossRefPubMed

75.

Hammache D, Yahi N, Maresca M, Pieroni G, Fantini J (1999) Human erythrocyte glycosphingolipids as alternative co-factors for human immunodeficiency virus type 1 entry: evidence for CD4 induced interactions between HIV-1 gp120 and reconstituted membrane microdomains of glycosphingolipids (Gb3 and GM3). J Virol 73:5244–5248PubMed

76.

Stephens EB, Tain C, Li Z, Narayan O, Gattone FH 2nd (2000) Rhesus macaques infected with macrophage-tropic simian immunodeficiency virus (SIVmacR71/17E) exhibit extensive focal segmental and global glomeruosclerosis. J Virol 72:8820–8832

77.

Bruggeman LA, Ross MD, Tanji N, Cara A, Dikman S, Gordon RE, Burns GC, D’Agati V, Winston JA, Klotman ME, Klotman PE (2000) Renal epithelium is a previously unrecognized site of HIV-infection. J Am Soc Nephrol 11:2079–2087PubMed

78.

Marras D, Bruggeman LA, Gao F, Tanji N, Mansukhani MM, Cara A, Ross MD, Gusella GL, Benson G, D’Agati V, Hahn BH, Klotman ME, Klotman PE (2002) Replication and compartmentalization of HIV-1 in kidney epithelium of patients with HIV-1 associated nephropathy. Nat Med 5:522–526CrossRef

79.

Winston JA, Bruggeman LA, Ross MD, Jacobson M, Ross L, D’Agati VD, Klotman PE, Klotman ME (2001). Nephropathy and establishment of a renal reservoir of HIV type 1 during primary infection. N Engl J Med 344:1979–1984CrossRefPubMed

80.

Husain M, Gussella GL, Klotman ME, Gelman IH, Ross MD, Schwartz EJ, Cara A, Klotman PE (2002) HIV-1 Nef induces proliferation and anchorage-independent growth in podocytes. J Am Soc Nephrol 13:1806–1815PubMed

81.

Dickie P (2000) Nef modulation of HIV type 1 gene expression and cytopathicity in tissues of HIV transgenic mice. AIDS Res Hum Retroviruses 16:777–790CrossRefPubMed

82.

Kajiyama W, Kopp JB, Marinos NJ, Notkins PE, Dickie P (2000) Glomerulosclerosis and viral gene expression in HIV-transgenic mice: role of nef. Kidney Int 58:1148–1159CrossRefPubMed

83.

Swingler S, Mann A, Jacque J-M, Brichachek B, Sasseville VG, Williams K, Lackner AA, Janoff EN, Wang R, Fisher D, Stevenson M (1999) HIV-1 Nef mediates lymphocyte chemotaxis and activation by infected macrophages. Nat Med 5:997–1003CrossRefPubMed

84.

Hanna Z, Kay DG, Rebai N, Guimond A, Jothy S, Jolicoeur P (1998) Nef harbors a major determinant of pathogenicity for an AIDS-like disease induced by HIV-1 in transgenic mice. Cell 95:163–175CrossRefPubMed

85.

Bodi I, Kimmel PL, Abraham AA, Svetkey LP, Klotman PE, Kopp JB. (1997) Renal TGF-β 1 in HIV-associated kidney diseases. Kidney Int 51:1568–1577PubMed

86.

Yamamoto T, Noble NA, Miller DE, Gold LL, Miller DE, Gold LL, Hishida A, Nagase M, Cohen AH, Border WY (1999) Increased levels of transforming growth factor-β in HIV-associated nephropathy. Kidney Int 55:579–592CrossRefPubMed

87.

Kopp JB, Factor VM, Mozes M, Nagy P, Sanderson N, Bottinger EP, Klotman PE, Thorgeirsson SS (1996) Transgenic mice with increased levels of TGF-beta 1 develop progressive renal disease. Lab Invest 74:991–1003PubMed

88.

Zietz C, Hotz B, Sturz M, Rauch E, Penning R, Lohrs U (1996) Aortic endothelium in HIV-1 infection. Chronic injury, activation and increased leukocyte adherence. Am J Pathol 149:1887–1898PubMed

89.

Ascheri G, Sgadari C, Bugarini R, Bogner J, Schatz O, Ensoli B, Sturzl M (2001). Serum concentration of fibroblast growth factor 2 are increased in HIV-1 type-infected patients and inversely correlated to survival probability. AIDS Res Hum Retroviruses 17:1035–1039CrossRefPubMed

90.

Wolf K, Tsakiris DA, Weber R, Erb P, Battegay M, for the Swiss HIV Cohort Study (2002). Antiretroviral therapy reduces markers of endothelial and coagulation activation in patients infected with human immunodeficiency virus type 1. J Infect Dis 185:456–462CrossRefPubMed

91.

Lindner V, Reidy MA (1991) Proliferation of smooth muscle cells after vascular injury is inhibited by an antibody against basic fibroblast growth factor. Proc Natl Acad Sci USA 88:3739–3743PubMed

92.

Linder V, Olson NE, Clowes AW, Reidy MA (1992) Inhibition of smooth muscle cell proliferation in injured rat arteries. J Clin Invest 90:2044–2049PubMed

93.

Sasaki T, Jyo Y, Tanda N, Kawakami Y, Nohno T, Tamai H, Osawa G (1999) Changes in glomerular epithelial cells induced by FGF-2 and FGF-2 neutralizing antibody in puromycin aminonucleoside nephropathy. Kidney Int 51:301–309

94.

Mazue G, Newman A, Scampini G, Torre PD, Hard GC, Iatropoulos MJ, Williams GM, Bagnasco (1993) The histopathology of kidneys changes in rats and monkeys following intravenous administration of massive doses of FCE 26184, human basic fibroblast growth factor. Toxicol Pathol 21:490–501PubMed

95.

Kriz W, Hahnel B, Rosener S, Elger M (1995) Long term treatment of rats with FGF-2 results in focal segmental glomerulosclerosis. Kidney Int 48:1435–1450PubMed

96.

Floege J, Kriz W, Schulze M, Susani M, Kerjaschki D, Mooney A, Couser WG, Koch KM (1995) Basic fibroblast growth factor augments podocyte injury and induces glomerulosclerosis in rats with experimental membranous nephropathy. J Clin Invest 96:2809–2819PubMed

97.

Rennke HG, Klein PS (1989) Pathogenesis and significance of nonprimary focal and segmental glomerulosclerosis. Am J Kidney Dis 13:443–456PubMed

98.

Tovo PA (2000) Highly active antiretroviral therapy inhibits cytokine production in HIV-uninfected subjects. AIDS 14:743–744CrossRefPubMed

99.

Lama G, Luongo I, Tirino G, Borreillo A, Carangio C, Salsano ME (2002) T-lymphocyte populations and cytokines in childhood nephrotic syndrome. Am J Kidney Dis 39:958–965CrossRefPubMed

100.

Gospodarowicz D, Ferrara N, Schweigerer L, Neufeld G (1987) Structural characterization and biological functions of fibroblast growth factor. Endocr Rev 8:95–114PubMed

101.

Powers CJ, McLeskey SW, Wellstein A (2000) Fibroblast growth factors, their receptors and signaling. Endocr Relat Cancer 7:165–197PubMed

102.

Ku PT, D’Amore PA (1995) Regulation of basic fibroblast growth factor (bFGF) gene expression and protein expression following its release from sublethally injured endothelial cells. J Cell Biochem 58:328–343PubMed

103.

Ray PE, Acheson D, Chitrakar R, Cnaan A, Gibbs K, Hirschman GH, Christen E, Trachtman and the Investigators of the Hemolytic Uremic Syndrome-Synsorb PK Multicenter Clinical Trial (2002) Basic fibroblast growth factor among children with diarrhea-associated hemolytic uremic syndrome. J Am Soc Nephrol 13:699–707PubMed

104.

Cozzolino F, Torcia M, Lucibello M, Morbidelli L, Ziche M, Platt J, Fabiani S, Stern D (1993) Interferon-alpha and interleukin 2 synergistically enhance basic fibroblast growth factor synthesis and induce release, promoting endothelial cell growth. J Clin Invest 91:2504–2512PubMed

105.

Samaniego F, Markham PD, Gallo RC, Ensoli B (1995) Inflammatory cytokines induce AIDS-Kaposi’s sarcoma-derived spindle cells to produce and release basic fibroblast growth factor and enhance Kaposi’s sarcoma-like lesion formation in nude mice. J Immunol 154:3582–3592PubMed

106.

Flaumenhaft R, Moscatelli D, Saksela O, Rifkin D (1989) Role of extracellular matrix in the action of basic fibroblast growth factor: matrix as a source of growth factor for long term stimulation of plasminogen activator production and DNA synthesis. J Cell Physiol 140:75–81PubMed

107.

Klagsbrun M, Baird A (1991) A dual receptor system is required for basic fibroblast growth factor activity. Cell 67:229–231CrossRefPubMed

108.

Ruoslahti E, Yamaguchi Y (1991) Proteoglycans as modulators of growth factor activities. Cell 64:867–869CrossRefPubMed

109.

Kriz W (1996) Progressive renal failure—inability of podocytes to replicate and the consequences for the development of glomerulosclerosis. Nephrol Dial Transplant 11:1738–1742

110.

Sasaki T, Hatta H, Osawa G (1999) Cytokines and podocyte injury: the mechanism of fibroblast growth factor-2 induced podocyte injury. Nephrol Dial Transplant 14 [Suppl 1]:33–34

111.

Floege J, Eng E, Linder V, Alpers CE, Young BA, Reidy MA, Johnson RJ (1992) Rat glomerular mesangial cells synthesize basic fibroblast growth factor. Release, upregulated synthesis and mitogenicity in mesangial proliferative glomerulonephritis. J Clin Invest 90:2362–2369PubMed

112.

Floege J, Eng E, Young BA, Alpers C, Barret TB, Bowen-Pope DF, Johnson RJ (1993) Infusion of platelet-derived growth factor or fibroblast growth factor induces selective glomerular mesangial cell proliferation and matrix accumulation in rats. J Clin Invest 92:2952–2962PubMed

113.

Naparsteck Y, Cohen IR, Fuks Z, Vlodavsky I (1984) Activated T lymphocytes produce a matrix-degrading heparan sulphate endoglycosidase. Nature 252:241–244

114.

Bashkin P, Doctrow S, Klagsbrun M, Svahn CM, Folkman J, Vlodavsky I (1989) Basic fibroblast growth factor binds to subendothelial extracellular matrix and is released by heparitinase and heparin-like molecules. Biochemistry 28:1737–1743PubMed

115.

Ensoli B, Gendelman R, Markham, Fiorelli V, Colombinin S, Raffeld M, Cafaro A, Chang H-K, Brady JN, Gallo RC (1994) Synergy between basic fibroblast growth factor and HIV-1 Tat protein in induction of Kaposi’s sarcoma. Nature 371:674–689CrossRefPubMed

116.

Mohan R, Sivak J, Ashton P, Russo LA, Pham BQ, Kasahara N, Raizman MB, Fini ME (2000) Circuminoids inhibit the angiogenic response stimulated by fibroblast growth factor-2, including expression of matrix metalloproteinase gelatinase B. J Biol Chem 275:10405–10412CrossRefPubMed

117.

Wu D, Kan M, Sato GH, Okamoto T, Sato JD (1991) Characterization and molecular cloning of a putative binding protein for heparin-binding growth factors. J Biol Chem 288:16778–16785

118.

Czubayko F, Smith RV, Chung HC, Wellstein A (1994) Tumor growth and angiogenesis induced by a secreted binding protein for fibroblast growth factor. J Biol Chem 269:28243–28248PubMed

119.

Czubayko F, Liaudet-Coopman ED, Aigner A, Tuveson AT, Berchem GJ, Wellstein A (1997) A secreted FGF-binding protein can serve as the angiogenic switch in human cancer. Nat Med 3:1137–1140PubMed

120.

Gupta GK, MiIner L, Linshaw MA, McCauley RG, Connors S, Folkman J, Bianchi DW (2000) Urinary basic fibroblast growth factor: a noninvasive marker of progressive cystic renal disease in a child. Am J Med Genet 17:132–135CrossRef

121.

Morita H, Shinzato T, David G, Mizutani A, Habuchi H, Fujita Y, Ito M, Asai J, Maeda K, Kimata K (1984) Basic fibroblast growth factor-binding domain of heparan sulfate in the human glomerulosclerosis and renal tubulointerstitial fibrosis. Lab Invest 71:528–535

122.

Clyton A, Thomas J, Thomas GJ, Davies M, Steadman R (2001) Cell surface heparan sulfate proteoglycans control the response of renal interstitial fibroblasts to fibroblast growth factor-2. Kidney Int 59:2084–2094CrossRefPubMed

123.

Patel M, Yanagishita M, Roderiquez G, Bou-Habib DC, Oravecz T, Hascall VC, Norcross MA (1993) Cell-surface heparan sulfate proteoglycans mediates HIV-1 infection of T-cell lines. AIDS Res Hum Retroviruses 9:167–174PubMed

124.

Ibrahim J, Griffin P, Coombe DR, Rider CC, James W (1999) Cell-surface heparan sulfate facilitates human immunodeficiency virus type 1 entry into some cells lines but not primary lymphocytes. Virus Res 60:159–169CrossRefPubMed

125.

Mondor I, Ugolini S, Sattentau QJ (1998) Human immunodeficiency virus type 1 attachment to HeLa CD4 cells is CD independent and gp120 dependent and requires cell surface heparans. J Virol 72:3623–3634PubMed

126.

Roderiquez G, Oravecz T, Yanagishita M, Bou-Habbi DC, Mostowski H, Norcross MA (1995) Mediation of human immunodeficiency virus-type 1 binding by interaction of cell surface heparan sulfate proteoglycans with the V3 region of envelope gp120-gp41. J Virol 69:2233–2239PubMed

127.

Moulard M, Lortat-Jacob H, Mondor I, Roca G, Wyatt R, Sodroski J, Zhao, Olson W, Kwong PD, Sattentau QJ (2000) Selective interactions of polyanions with basic surfaces on HIV-1 gp120. J Virol 74:1948–1960CrossRefPubMed

128.

Mitusya H, Looney DJ, Kuno S, Ueno R, Wong-Staal F, Broder S (1988). Dextran sulfate suppression of viruses in the HIV-family: inhibition of virion binding to CD4+ cells. Science 240:646–648PubMed

129.

Rusnati M, Tulipano G, Urbinati C, Tanghetti E, Giuliani R, Giacca M, Ciomei M, Corallini A, Presta M (1998) The basic domain in HIV-1 Tat protein as a target for polysulfonated heparin-mimicking extracellular Tat antagonist. J Biol Chem 273:16027–16037CrossRefPubMed

130.

Oravecz T, Pall M, Wang J, Roderiquez G, Ditto M, Norcross MA (1997) Regulation of anti-HIV-1 activity of RANTES by heparan sulfate proteoglycans. J Immunol 159:4587–4592PubMed

131.

Luster AD (1998) Chemokines—chemotactic cytokines that mediate inflammation. N Engl J Med 338:436–445CrossRefPubMed

132.

Gordon CJ, Muesing MA, Proudfoot AE, Power CA, Moore JP, Trkola A (1999) Enhancement of HIV-type 1 infection by the CC-chemokine RANTES is independent of the mechanism of virus-cell fusion. J Virol 73:684–694PubMed

133.

Albini A, Ferrini S, Benelli R, Sforzini S, Giunciuglio D, Aluigi MG, Proudfoot AEI, Alouani S, Wells TNC, Mariani G, Rabin RL, Farber JM, Noon DM (1998) HIV-1 Tat protein mimicry of chemokines. Proc Natl Acad Sci U S A 95:13153–13158CrossRefPubMed

134.

Tyago M, Rusnati M, Presta M, Giacca M (2001) Internalization of HIV-1 Tat requires cell surface heparan sulfate proteoglycans. J Biol Chem 276:3254–3261CrossRefPubMed

135.

Jia H, Lohr M, Jezequel S, Davis D, Shaikh S, Selwood D, Zachary I (2001) Cysteine-rich and basic domain HIV-1 Tat peptides inhibit angiogenesis and induce endothelial cell apoptosis. Biochem Biophy Res Commun 283:469–479CrossRef

136.

Liu X-H, Hadley TJ, Xu X, Peiper SC, Ray PE (1999) Up-regulation of Duffy antigen receptor expression in children with renal disease. Kidney Int 55:1491–1500CrossRefPubMed

137.

Hadley TJ, Peiper SC (1997) From malaria to chemokine receptor: the emerging physiologic role of the Duffy blood group antigen. Blood 89:3077–3091PubMed

138.

Lachgar A, Jaureguiberry G, Le Buenac H, Bizzini B, Zagury JF, Rappaport J, Zagury D (1998) Binding of HIV-1 to RBC involves the Duffy antigen receptors for chemokines (DARC). Biomed Pharmacother 52:436–439CrossRefPubMed

139.

Darbone WC, Rice GC, Mohler MA, Apple T, Hebert C, Valente AJ, Baker JB (1991) Red cells are a sink for interleukin 8, a leukocyte chemotaxin. J Clin Invest 88:1362–1369PubMed

140.

Dawson TC, Lentsch AB, Wang Z, Cowhig JE, Rot N, Maeda N, Peiper SC (2000) Exaggerated response to endotoxin in mice lacking the Duffy antigen/receptor for chemokines (DARC). Blood 96:1681–1684PubMed

141.

Hadley TJ, Lu ZH, Wasniowska K, Martin AW, Peiper SC, Hesselgesser J (1994) Postcapillary venule endothelial cells in kidney express a multispecific chemokine receptor that is structural and functionally identically to the erythroid isoform, which is the Duffy blood group antigen. J Clin Invest 94:985–991PubMed

142.

Woolley IJ, Kalyjian R, Valdez H, Hamza H, Jacobs G, Lederman MM, Zimmerman PA (2001) HIV-nephropathy and the Duffy antigen/antigen receptor for chemokines in African Americans. J Nephrol 14:384–387PubMed

143.

Kim JM, Wu H, Green G, Winkler CA, Kopp JB, Miner JH, Unanue ER, Shaw AS (2003) CD2-associated protein haploinsufficiency is linked to glomerular disease susceptibility. Science 300:1298–1300CrossRefPubMed

144.

D’Agati V (2003) Pathologic classification of focal segmental glomerulosclerosis. Semin Nephrol 23:117–134CrossRefPubMed

145.

Singh HK, Baldree LA, McKenney DW, Hogan SL, Jennette JC (2000) Idiopathic collapsing glomerulopathy in children. Pediatr Nephrol 14:132–137CrossRefPubMed

146.

Moudgil A, Nast CC, Bagga A, Wei L, Nurmaamet A, Cohen AH, Hordan SC, Toyoda M (2001) Association of parvovirus B19 infection with idiopathic collapsing glomerulopathy. Kidney Int 59:2126–2133CrossRefPubMed

147.

Moore PS, Chang Y (1998) Kaposi’s sarcoma (KS), KS-associated herpesvirus, and the criteria for causality in the age of molecular biology. Am J Epidemiol 147:217–221PubMed

148.

Montaner S, Sodhi A, Molinolo A, Bugge TH, Sawai ET, He Y, Li Y, Ray PE, Gutkind JS (2003) Endothelial infection with KSHV genes in vivo reveals that vGPCR initiates Kaposi’s sarcomagenesis and can promote the tumorigenic potential of viral latent genes. Cancer Cell 3:23–36CrossRefPubMed

149.

Pomerantz FJ, Horn DL (2003) Twenty years of therapy for HIV-1 infection. Nature Med 9:867–873CrossRefPubMed

150.

Rao TK (2003) Human immunodeficiency virus infection in end-stage renal disease patients. Semin Dial 16:233–244CrossRefPubMed

151.

Szczech LA, Kalayjian R, Rodriguez R, Gupta D, Coladonato J, Winston J; Adult AIDS Clinical Trial Group Renal Complications Committee (2003) The clinical characterisitics and antiretroviral dosing patterns of HIV-infected patients receiving dialysis. Kidney Int 63:2295–2301CrossRefPubMed

152.

Rao TK (2001) Human immunodeficiency virus infection and renal failure. Infect Dis Clin North Am15:833–851

153.

Sothinathan R, Briggs WA, Eustace JA (2001) Treatment of HIV-associated nephropathy. AIDS Patient Care STDs 15:363–371CrossRefPubMed

154.

Ifudu O, Rao TK, Tan CC, Fleischman H, Chirgwin K, Friedman EA (1995) Zidovudine is beneficial in human immunodeficiency virus associated nephropathy. Am J Nephrol 15:217–221PubMed

155.

Viani RM, Danker WM, Muelenaer PA, Spector SA (1999) Resolution of HIV-associated nephropathy nephrotic syndrome with highly active antiretroviral therapy delivered by gastrostomy tube. Pediatrics 104:1394–1396PubMed

156.

Wali RK, Drachenberg CI, Papdimitrious JC, Keay S, Ramos E (1998) HIV-1 associated nephropathy and response to highly-active antiretroviral therapy (letter). Lancet 352:783–784CrossRefPubMed

157.

Hedayati SS, Reddan DN, Szcech LA (2003) HIV-associated nephropathy: a review of the epidemiology and clinical course in the HAART era. AIDS Patient Care 17:57–63CrossRef

158.

Kirchener JT (2002) Resolution of renal failure after initiation of HAART; 3 cases and a discussion of the literature. AIDS Read 12:103–105, 110–112PubMed

159.

Sgadari C, Monini P, Barillari G, Ensoli B (2000) Use of HIV-1 protease inhibitors to block Kaposi’s sarcoma and tumor growth. Lancet 4:537–547

160.

Pati S, Peiser CB, Dufraine J, Bryant JL, Reitz MS, Weichold FF (2002) Antitumorigenic effects of HIV protease inhibitor ritonavir: inhibition of Kaposi sarcoma. Blood 99:1–9CrossRef

161.

Sgadari C, Barillari G, Toschi E, Carlei D, Bacigalupo I, Baccarini S, Palladino C, Leone P, Bugarini R, Malavas L, Cafaro A, Falchi M, Valdembri D, Rezza G, Bussolino F, Monini P, Ensoli B (2002) HIV-protease inhibitors are potent anti-angiogenic molecules and promote regression of Kaposi sarcoma. Nature Med 8:225–232CrossRefPubMed

162.

Burns GC, Matute R, Onyema D, Davis I, Toth I (1994). Response to inhibition of angiotensin-converting enzyme in human immunodeficiency virus-associated nephropathy: a case report. Am J Kidney Dis 23:441–443PubMed

163.

Kimmel PL, Mishkin GJ, Umana WO (1996). Captopril and renal survival in patients with human immunodeficiency virus nephropathy. Am J Kidney Dis 28:202–208PubMed

164.

Wei A, Burns GC, Williams BA, Mohammed NB, Sivak SL (2003) Long-term renal survival in HIV-associated nephropathy with angiotensin-converting enzyme inhibition. Kidney Int 64:1462–1471CrossRefPubMed

165.

Ouellette DR, Kelly JW, Anders GT (1992) Serum angiotensin-converting enzyme level is elevated in patients with human immunodeficiency virus infection. Arch Intern Med 152:321–324CrossRefPubMed

166.

Bird JE, Durham SK, Giancarli MR, Giancarli MR, Gitlitz PH, Pandya DG, Dambach DM, Mozes MM, Kopp JB (1998) Captopril prevents nephropathy in HIV-transgenic mice. J Am Soc Nephrol 9:1441–1447PubMed

167.

Zhang SL, To C, Chen X, Filep JG, Tang SS, Ingelfinger JR, Chan JS (2002) Essential role(s) of the intrarenal renin-angiotensin system in transforming growth factor beta 1 gene expression and induction of hypertrophy of rat kidney proximal tubular cells in high glucose. J Am Soc Nephrol 13:302–312PubMed

168.

Guijarro C, Egido J (2001) Transcription factor-kappa B (NF-kappa B) and renal disease. Kidney Int 59:415–424CrossRefPubMed

169.

Nguyen L, Ward WF, Tsao C, Molteni A (1994) Captopril inhibits proliferation of human lung fibroblasts in culture: a potential antifibrotic mechanism. Proc Soc Exp Biol Med 205:80–84PubMed

170.

Fishel RS, Thourani V, Eisenberg SJ, Shai SY, Corson MA, Nabel EG, Bernstein KE, Berk BC (1995) Fibroblast growth factor stimulates angiotensin converting enzyme expression in vascular smooth muscle cells. Possible mediator of the response to vascular injury. J Clin Invest 95:377–387PubMed

171.

Volpert OV, Ward WF, Lingen MW, Chesler L, Solt DB, Johnson MD, Molteni A, Polverini PJ, Bouck NP (1996) Captopril inhibits angiogenesis and slows the growth of experimental tumors in rats. J Clin Invest 98:671–679PubMed

172.

Merchan JR, Chan B, Kale S, Schipper LE, Sukhatmen VP (2003) In vitro and in vivo induction of antiangiogenic activity by plasminogen activators and captopril. J Natl Cancer Inst 95:388–399CrossRefPubMed

173.

Vogt B, Frey FJ (1997) Inhibition of angiogenesis in Kaposi’s sarcoma by captopril (letter). Lancet 349:1148PubMed

174.

Barr Jr M (1994) Teratogen update. Angiotensin-converting enzyme inhibitors. Teratology 50:399–409PubMed

175.

The International Study of Kidney Disease in Children (1981) The primary nephrotic syndrome in children. Identification of patients with minimal change nephrotic syndrome from initial response to prednisone. J Pediatr 98:561-564PubMed

176.

Smith MC, Austen JL, Carey JT, Emancipator SN, Herbener T, Gripshover B, Mbanefo C, Phinney M, Rahman M, Salata RA, Weigel K, Kalayjian RC (1996) Prednisone improves renal function and proteinuria in human immunodeficiency virus-associated nephropathy. Am J Med 101:41–48CrossRefPubMed

177.

Rao TK (1997) Prednisone, renal function, and proteinuria in immunodeficiency virus-associated nephropathy. Am J Kidney Dis 30:156–159PubMed

178.

Eustace JA, Nuermberger E, Choi M, Scheel PJ, Moore R, Briggs WA (2000) Cohort study of the treatment of severe HIV-associated nephropathy with corticosteroids. Kidney Int 58:1253–1260CrossRefPubMed

179.

Szczech LA, Edwards LJ, Sanders LL, Horst C van der, Bartlett JA, Heald AE, Svetkey LP (2002) Protease inhibitors are associated with a slowed progression of HIV-related renal diseases. Clin Nephrol 57:336–341PubMed

180.

Stock P, Roland ME, Carlson L, Freise CE, Roberts JP, Hirose R, Terrault NA, Frassetto LA, Palefsky JM, Tomlanovich SJ, Ascher NL (2003) Kidney and liver transplantation in human immunodeficiency virus-infected patients: a pilot safety and efficacy study. Transplantation 76:370–375CrossRefPubMed

181.

Singh A, Tejani C, Tejani A (1999) One-center experience with cyclosporine in refractory nephrotic syndrome in children. Pediatr Nephrol 13:26–32CrossRefPubMed

182.

Lalezari JP, Henry K, O’Hearn M, Montaner JS, Piliero PJ, Trottier B, Walmsley S, Cohen S, Kuritzkes DR, Eon JJ, Chung J, DeMasi R, Donatacci L, Drobnes C, Delehanty J, Salgo M; TORO 1 Study Group (2003). Efuvirtide, an HIV-1 fusion inhibitor, for drug-resistant HIV infection in North and South America. N Engl J Med 348:2175–2185CrossRefPubMed

Titel: A 20-year history of childhood HIV-associated nephropathy
verfasst von: Patricio E. Ray
Lian Xu
Tamara Rakusan
Xue-Hui Liu
Publikationsdatum: 01.10.2004
Verlag: Springer-Verlag
Erschienen in: Pediatric Nephrology / Ausgabe 10/2004
Print ISSN: 0931-041X
Elektronische ISSN: 1432-198X
DOI: https://doi.org/10.1007/s00467-004-1558-1

Neu im Fachgebiet Pädiatrie

Bei Amblyopie früher abkleben als bisher empfohlen?

22.05.2024 Fehlsichtigkeit Nachrichten

Bei Amblyopie ist das frühzeitige Abkleben des kontralateralen Auges in den meisten Fällen wohl effektiver als der Therapiestandard mit zunächst mehrmonatigem Brilletragen.

„Übersichtlicher Wegweiser“: Lauterbachs umstrittener Klinik-Atlas ist online

17.05.2024 Klinik aktuell Nachrichten

Sie sei „ethisch geboten“, meint Gesundheitsminister Karl Lauterbach: mehr Transparenz über die Qualität von Klinikbehandlungen. Um sie abzubilden, lässt er gegen den Widerstand vieler Länder einen virtuellen Klinik-Atlas freischalten.

ADHS-Medikation erhöht das kardiovaskuläre Risiko

16.05.2024 Herzinsuffizienz Nachrichten

Erwachsene, die Medikamente gegen das Aufmerksamkeitsdefizit-Hyperaktivitätssyndrom einnehmen, laufen offenbar erhöhte Gefahr, an Herzschwäche zu erkranken oder einen Schlaganfall zu erleiden. Es scheint eine Dosis-Wirkungs-Beziehung zu bestehen.

Erstmanifestation eines Diabetes-Typ-1 bei Kindern: Ein Notfall!

16.05.2024 DDG-Jahrestagung 2024 Kongressbericht

Manifestiert sich ein Typ-1-Diabetes bei Kindern, ist das ein Notfall – ebenso wie eine diabetische Ketoazidose. Die Grundsäulen der Therapie bestehen aus Rehydratation, Insulin und Kaliumgabe. Insulin ist das Medikament der Wahl zur Behandlung der Ketoazidose.

Update Pädiatrie

Bestellen Sie unseren Fach-Newsletter und bleiben Sie gut informiert.

Newsletter bestellen

Live-Webinar "Urologie und Sexualmedizin in der Praxis"

Springer Medizin

A 20-year history of childhood HIV-associated nephropathy

Abstract

Neu im Fachgebiet Pädiatrie

Bei Amblyopie früher abkleben als bisher empfohlen?

„Übersichtlicher Wegweiser“: Lauterbachs umstrittener Klinik-Atlas ist online

ADHS-Medikation erhöht das kardiovaskuläre Risiko

Erstmanifestation eines Diabetes-Typ-1 bei Kindern: Ein Notfall!

Update Pädiatrie

Live-Webinar "Urologie und Sexualmedizin in der Praxis"

Springer Medizin

Abstract

Bitte loggen Sie sich ein, um Zugang zu diesem Inhalt zu erhalten

Weitere Artikel der Ausgabe 10/2004

Up-regulation of interleukin-2 mRNA in children with idiopathic nephrotic syndrome

A novel mutation of WT1 exon 9 in a patient with Denys-Drash syndrome and pyloric stenosis

Paroxysmal nocturnal hemoglobinuria in a girl with hemolysis and “hematuria”

Lack of seasonal variations in urinary calcium/creatinine ratio in school-age children

Two different therapeutic regimes in patients with sequelae of hemolytic-uremic syndrome

Parathyroid hormone increases cytosolic calcium in neonatal nephron through protein kinase C pathway

Neu im Fachgebiet Pädiatrie

Bei Amblyopie früher abkleben als bisher empfohlen?

„Übersichtlicher Wegweiser“: Lauterbachs umstrittener Klinik-Atlas ist online

ADHS-Medikation erhöht das kardiovaskuläre Risiko

Erstmanifestation eines Diabetes-Typ-1 bei Kindern: Ein Notfall!

Update Pädiatrie